2018. 06. Signed the MOU of Vaccine Development with the International Vaccine Institute
2018. 05. Signed the Exclusive License Right of Vaccine Development based on VSV vector Technology with UWO
2018. 02. Selected as a research and development project for the National R&D of the Korea Centers for Disease Control and Prevention
2017. 10. Conducted the Type C meeting with US FDA to discuss the plan for Phase II clinical trial and improved manufacturing processes
2017. 01. Executed contract for Phase II clinical trial management and operation with Covance, USA
20152016. 11. Published the results of Phase I clinical trial in Retrovirology
2014. 11. Executed the clinical material production contract for Phase II clinical trial with BioMARC, USA
2014. 06. Completed Phase I clinical trial of SAV001
2012. 03. Administered SAV001 to the first patient for the Phase I trials
Selected as AIDS vaccine development fund beneficiary by Bill and Melinda Gates Foundation and the government of Canada
2011. 12. US FDA approved Sumagen's IND for Phase I Human Clinical Trials of SAV001, the HIV vaccine candidate
20102011. 06. Submitted IND to US FDA for Phase I Human Clinical Trials
2009. 11. GNCO Co. Ltd. invested 8 Billion Korean Won for Sumagen and increased its share by 35.22%
2009. 02. GNCO Co. Ltd. invested 6 Billion Korean Won for Sumagen and became 18.89% shareholder
2006. 12. Entered into Investment Agreement for Hepatitis C vaccine development with UWO
2006. 06. Obtained US patents for HIV/AIDS vaccine development technology
20052005. 11. Curocom (Curo Group) acquired 100% of Sumagen shares for 20.75 Billion Korean Won
Mr. Kim, Dong-joon, Vice Chairman of Curo Group, was inaugurated as the CEO
2002. 11. Received the research fund from SK Co., Ltd. in amount of USD 660,000
2001. 08. Entered into Investment Agreement for HIV/AIDS vaccine development with UWO
Executed Exclusive License Agreement for HIV/AIDS vaccine development with UWO
20002000. 09. Established by Dr. Kang, Chil-Yong (UWO)